sectors such as pharmacy, horticulture, plant breeding (for food, agriculture and ornamentals), nutraceuticals, cosmetics and biotechnology industries, which either use natural compounds or synthesise their own material.
In what follows, we will first give an overview of the specific legal provisions on ABS in Germany and a brief overview (in Section II) at how access to biological material is regulated. In Section III, we focus on the different activities and the diversity of actors concerned with access and use of genetic resources from foreign countries, in compliance with the CBD, followed by our conclusions (in Section IV).
I Legal Provisions on Access and Benefit-Sharing in Germany
The Nagoya Protocol will be implemented EU-wide through the new EU Regulation No 511/2014 of 16 April 2014 on compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation in the Union (hereinafter referred to as the "EU Regulation on ABS").5 This regulation entered into force on 9 June 2014 and applies as of 12 October 2014, when the Nagoya Protocol itself enters into force worldwide and for the European Union. However, the most relevant Articles 4, 7 and 9 of the EU Regulation on ABS will apply only one year after that,6 because additional measures need to be put in place before they can be applied. The EU Regulation on ABS implements all relevant international obligations uniformly on EU level that concern the use of genetic resources, especially Articles 15, 16 and 17 of the Nagoya Protocol. The regulation of access remains with the member states.7 Germany is currently in the process of adopting a law to complement the implementation of the Nagoya Protocol on the national level and to implement the parts of the EU Regulation on ABS that need to be substantiated.8 Germany is a federal state, the competency to legislate is split between the 
